


Immune Checkpoint Inhibitors: HDR UK Medicines Programme Cancer-Related Resource

Data range for infographic: 17.01.2000-09.10.2023 Other extended time periods are available on request

Highly granular dataset of 1,000 cancer patients treated with checkpoint inhibitors, tracking acute healthcare visits, demographics, side effects, physiology, blood results, outpatient activity, consultations, prescriptions, treatments and survival.



Inhibitor categories


21%

Immune checkpoint inhibitor




48% of patients are treated with Nivolumab, a PD-1 inhibitor with a median total cycle of 4. Followed by **41%** of patients treated with Pembrolizumab with a median total cycle of 6.





14% diagnosed with melanomas


Other cancer types are available.



therapy Other therapy are available.

Inpatient care

- 23,673 Hospitalised spells; containing 1,000 unique patients admitted to critical care
- 29K days worth of hospital data with an average in-hospital length of stay of 1 days
- In-hospital mortality rate of 0.6% and 98% of patients surviving 12 months after discharge
- The median National Early Warning Score is 1 and the median Clinical Frailty Scale is 4



Consultations

Top 5 consultation directorates are:

- **4K** Emergency medicine
- **4K** Oncology
- **2K** Emergency department





MR

Other medical imaging are available.

- **361** Plastic surgery
- 358 General medicine



Other associated data available upon request

Contact us at: www.pioneerdatahub.co.uk pioneer@uhb.nhs.uk